Safety and efficacy of daratumumab-based regimens in elderly (≥75 y) patients (Pts) with relapsed or refractory multiple myeloma (RRMM): Subgroup analysis of POLLUX and CASTOR.

被引：2
|
作者：
Mateos, Maria-Victoria
Spencer, Andrew
Nooka, Ajay K.
Pour, Ludek
Weisel, Katja C.
Cavo, Michele
Laubach, Jacob
Cook, Gordon
Iida, Shinsuke
Benboubker, Lotfi
Usmani, Saad Zafar
Yoon, Sung-Soo
Bahlis, Nizar J.
Chiu, Christopher
Schecter, Jordan Mark
Wu, Kaida
Qin, Xiang
Soong, David
Dimopoulos, Meletios A.
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.8033
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8033
引用
收藏
页数：5
相关论文
共 50 条
  • [1] DARATUMUMAB-BASED COMBINATION REGIMENS IN ELDERLY (≥75 YEARS) PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: SUBGROUP ANALYSIS OF THE PHASE 3 CASTOR AND POLLUX STUDIES
    Mateos, M. -V.
    Spencer, A.
    Nooka, A.
    Pour, L.
    Weisel, K.
    Cavo, M.
    Laubach, J.
    Cook, G.
    Iida, S.
    Benboubker, L.
    Usmani, S. Z.
    Yoon, S. -S.
    Bahlis, N.
    Chiu, C.
    Schecter, J.
    Wu, K.
    Qin, X.
    Soong, D.
    Dimopoulos, M. A.
    HAEMATOLOGICA, 2017, 102 : 109 - 109
  • [2] Daratumumab-Based Regimens with Prior Carfilzomib in Patients with Relapsed Refractory Multiple Myeloma (RRMM)
    Tungesvik, Alexandre
    Huang, Jessica
    Sudalagunta, Praneeth
    Dimaggio, Elizabeth
    De Avila, Gabe
    Tandon, Ankita
    Nelson, Rebeccah
    Olson, Laura
    Tobon, Katherine
    Shain, Kenneth
    Brayer, Jason
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S327 - S328
  • [3] Efficacy and safety of daratumumab, bortezomib, and dexamethasone (D-Vd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk: Updated subgroup analysis of CASTOR.
    Weisel, Katja
    Spencer, Andrew
    Lentzsch, Suzanne
    Avet-Loiseau, Herve
    Mark, Tomer M.
    Spicka, Ivan
    Bosi, Alberto
    Hungria, Vania T. M.
    Cavo, Michele
    Lee, Je-Jung
    Nooka, Ajay K.
    Quach, Hang
    Munder, Markus
    Beksac, Meral
    Sonneveld, Pieter
    Soong, David
    Ukropec, Jon
    Qi, Ming
    Mateos, Maria-Victoria
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [4] Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies
    Mateos, Maria-Victoria
    Spencer, Andrew
    Nooka, Ajay K.
    Pour, Ludek
    Weisel, Katja
    Cavo, Michele
    Laubach, Jacob P.
    Cook, Gordon
    Iida, Shinsuke
    Benboubker, Lotfi
    Usmani, Saad Z.
    Yoon, Sung-Soo
    Bahlis, Nizar J.
    Chiu, Christopher
    Ukropec, Jon
    Schecter, Jordan M.
    Qin, Xiang
    O'Rourke, Lisa
    Dimopoulos, Meletios A.
    HAEMATOLOGICA, 2020, 105 (02) : 468 - 477
  • [5] Daratumumab-based combination therapies (DCT) in heavily-pretreated patients (pts) with relapsed and/or refractory multiple myeloma (RRMM).
    Lakshman, Arjun
    Abeykoon, Jithma P.
    Kumar, Shaji
    Rajkumar, S. Vincent
    Kourelis, Taxiarchis
    Buadi, Francis
    Dingli, David
    Lacy, Martha
    Gonsalves, Wilson I.
    Dispenzieri, Angela
    Kyle, Robert A.
    Lin, Yi
    Go, Ronald S.
    Warsame, Rahma M.
    Hayman, Suzanne R.
    Russell, Stephen
    Leung, Nelson
    Gertz, Morie A.
    Kapoor, Prashant
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [6] Efficacy and Safety of Daratumumab-Based Regimens in Patients with Relapsed/Refractory Multiple Myeloma - A Systematic Literature Review and Network Meta-analysis
    Dimopoulos, Meletios
    Weisel, Katja
    Kaufman, Jonathan L.
    Sonneveld, Pieter
    Rizzo, Maria
    Xu, Yingxin
    Fahrbach, Kyle
    Gaudig, Maren
    Slavcev, Mary
    Lam, Annette
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E63 - E63
  • [7] Efficacy and safety of daratumumab, lenalidomide, and dexamethasone (D-Rd) in relapsed or refractory multiple myeloma (RRMM): Updated subgroup analysis of POLLUX based on cytogenetic risk.
    Kaufman, Jonathan L.
    Dimopoulos, Meletios A.
    Leiba, Merav
    Morton, James
    Ho, P. Joy
    Kim, Kihyun
    Moreau, Philippe
    Sutherland, Heather J.
    Iida, Shinsuke
    Kim, Jin Seok
    Prince, H. Miles
    Rocafiguera, Albert Oriol
    Bahlis, Nizar J.
    Chari, Ajai
    Avet-Loiseau, Herve
    Chiu, Christopher
    Soong, David
    Ukropec, Jon
    Qi, Ming
    San Miguel, Jesus
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [8] EFFICACY OF DARATUMUMAB-BASED REGIMENS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA - A SYSTEMATIC LITERATURE REVIEW AND NETWORK META-ANALYSIS
    Dimopoulos, M. A.
    Weisel, K.
    Kaufman, J.
    Sonneveld, P.
    Rizzo, M.
    Xu, Y.
    Fahrbach, K.
    Gaudig, M.
    Slavcev, M.
    Dearden, L.
    Lam, A.
    HAEMATOLOGICA, 2017, 102 : 525 - 526
  • [9] Response Kinetics of Daratumumab-Based Regimens in Patients with Newly Diagnosed or Refractory/Relapsed Multiple Myeloma
    Wang, Jiasheng
    Arroyo-Suarez, Raul
    Tse, William
    BLOOD, 2021, 138 : 3806 - +
  • [10] UPDATED EFFICACY AND SAFETY ANALYSIS OF DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE (DRd) VERSUS LENALIDOMIDE AND DEXAMETHASONE (Rd) FOR RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM; POLLUX)
    Moreau, P.
    White, D.
    Benboubker, L.
    Cook, G.
    Leiba, M.
    Morton, J.
    Ho, P. J.
    Kim, K.
    Takezako, N.
    Trivedi, S.
    Wu, K.
    Casneuf, T.
    Chiu, C.
    Schecter, J. M.
    Dimopoulos, M. A.
    HAEMATOLOGICA, 2018, 103 : 31 - 31
12345